Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 435702, 11 pages
Research Article

Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical Trial

1Traditional & Complementary Medicine Research Program, Health Innovations Research Institute, School of Health Sciences, RMIT University, Bundoora, VIC 3083, Australia
2China Medical University and Hospital, Taichung City 40447, Taiwan
3School of Mathematics & Geospatial Sciences, RMIT University, Bundoora, VIC 3083, Australia
4School of Applied Sciences, RMIT University, Bundoora, VIC 3083, Australia
5Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China

Received 21 October 2011; Revised 20 January 2012; Accepted 23 January 2012

Academic Editor: Wolfgang Weidenhammer

Copyright © 2012 George Binh Lenon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. This study was to evaluate the efficacy and safety of a Chinese herbal medicine formula (RCM-104) for the management of simple obesity. Method. Obese subjects aged between 18 and 60 years were selected for 12-week, double-blind, randomized, placebo-controlled trial. Subjects were randomly assigned to take 4 capsules of either the RCM-104 formula ( 𝑛 = 5 9 ) or placebo ( 𝑛 = 5 8 ), 3 times daily for 12 weeks. Measures of BW, BMI and WC, HC, WHR and BF composition were assessed at baseline and once every four weeks during the 12 week treatment period. Results. Of the 117 subjects randomised, 92 were included in the ITT analysis. The weight, BMI and BF in RCM-104 group were reduced by 1.5 kg, 0.6 kg/m2 and 0.9% and those in the placebo group were increased by 0.5 kg, 0.2 kg/m2 and 0.1% respectively. There were significant differences in BW and BMI ( 𝑃 < 0 . 0 5 ) between the two groups. Eleven items of the WLQOQ were significantly improved in the RCM-104 group while only 2 items were significantly improved in the placebo group. Adverse events were minor in both groups. Conclusion. RCM-104 treatment appears to be well tolerated and beneficial in reducing BW and BMI in obese subjects.